drugset / Trial / NCT02059733

Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism

NCT02059733

Phase 2 Completed 72 enrolled Chang Gung Memorial Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

This study will compare the brain uptake of 18F- DTBZ in 20 patients with PD, 20 patients with MSA, 20 patients with PSP, 20 patients with CBS, and 20 patients with VaP, 20 patients with ET, and 10 patients with DT.

Timeline

Start
2013-02
Primary completion
2018-07-31
Completion
2018-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-DTBZ Diagnostic / imaging agent 370 mbq Intravenous

Indications